Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 17, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

May 31, 2021

Conditions
Impaired Glucose Tolerance
Interventions
DRUG

Nicotinic acid

oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis

OTHER

[7,7,8,8-2H]-palmitate

using i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to +360 min

OTHER

[U-13C]-palmitate

oral administration of \[U-13C\]-palmitate (0.2 g mixed into the liquid meal) at time 0 min

PROCEDURE

Biopsy

A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1

OTHER

liquid meal

At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes

Trial Locations (1)

J1H 5N4

centre de recherche du CHUS, Sherbrooke

All Listed Sponsors
lead

Université de Sherbrooke

OTHER

NCT02808182 - Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D) | Biotech Hunter | Biotech Hunter